Moody's rates Boston Scientific notes Baa3

Moody's Investors Service said it assigned a Baa3 rating to Boston Scientific Corp.'s $1.2 billion new senior unsecured note offering and a prospective Baa3 rating to the company's new senior unsecured shelf registration.

The outlook is stable.

Moody's noted that Boston Scientific's Baa3 ratings reflect very high leverage and significantly weaker financial ratios following the recent Guidant transaction.

In light of the acquisition, the ratings also incorporate Moody's belief that Boston Scientific's willingness to use debt in combination with equity to finance strategic acquisitions is very high.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.